Veradermics (MANE) is down 4.4% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver appears to be share-supply pressure tied to the expiration of post-IPO lock-up restrictions. This could be because a late-April SEC prospectus said 20,000,170 previously locked-up shares would become eligible for resale on August 2, 2026, which can pressure a stock even without a new negative operating update.
Details:
An SEC prospectus for Veradermics stated that 20,000,170 shares held by pre-IPO owners were scheduled to become available for resale on August 2, 2026, subject to certain limits and agreements.The same filing warned that actual sales, or even the expectation that a large block could be sold, could reduce the market price of the common stock.Veradermics' most recent notable company update in mid-July highlighted positive topline Phase 2 data for VDPHL01 in female pattern hair loss, so the latest decline does not appear to be tied to an obvious negative clinical announcement.Earlier company materials also said Veradermics is funded into 2030 and is targeting multiple data milestones in the second half of 2026, which points more toward a technical trading catalyst than a balance-sheet shock.Sources:
SEC, Veradermics, Nasdaq
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$MANE Insider Trading Activity
$MANE insiders have traded $MANE stock on the open market 26 times in the past 6 months. Of those trades, 26 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MANE stock by insiders over the last 6 months:
- PATRICK G ENRIGHT has made 2 purchases buying 1,075,000 shares for an estimated $18,275,000 and 0 sales.
- CAPITAL PARTNERS V, LLC LONGITUDE has made 2 purchases buying 1,075,000 shares for an estimated $18,275,000 and 0 sales.
- CAPITAL MANAGEMENT, LLC SUVRETTA has made 19 purchases buying 282,674 shares for an estimated $10,542,477 and 0 sales.
- JOHN W CHILDS purchased 294,117 shares for an estimated $4,999,989
- VLAD CORIC has made 2 purchases buying 117,646 shares for an estimated $1,999,982 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Quiver Alerts
Receive MANE Data Alerts
Get market-moving data, filings, and signals for MANE in real time.
Sign Up
$MANE Hedge Fund Activity
We have seen 80 institutional investors add shares of $MANE stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUVRETTA CAPITAL MANAGEMENT, LLC added 4,168,970 shares (+inf%) to their portfolio in Q1 2026, for an estimated $263,270,455
- SR ONE CAPITAL MANAGEMENT, LP added 2,401,868 shares (+inf%) to their portfolio in Q1 2026, for an estimated $151,677,964
- CITADEL ADVISORS LLC added 1,825,672 shares (+inf%) to their portfolio in Q1 2026, for an estimated $115,291,186
- FMR LLC added 1,792,909 shares (+inf%) to their portfolio in Q1 2026, for an estimated $113,222,203
- VIKING GLOBAL INVESTORS LP added 1,690,555 shares (+inf%) to their portfolio in Q1 2026, for an estimated $106,758,548
- SIREN, L.L.C. added 1,505,374 shares (+inf%) to their portfolio in Q1 2026, for an estimated $95,064,368
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,100,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $69,465,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MANE Analyst Ratings
Wall Street analysts have issued reports on $MANE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 06/02/2026
- Cantor Fitzgerald issued a "Overweight" rating on 03/02/2026
To track analyst ratings and price targets for $MANE, check out Quiver Quantitative's $MANE forecast page.
$MANE Price Targets
Multiple analysts have issued price targets for $MANE recently. We have seen 5 analysts offer price targets for $MANE in the last 6 months, with a median target of $135.0.
Here are some recent targets:
- Roger Song from Jefferies set a target price of $182.0 on 07/07/2026
- Rami Katkhuda from LifeSci Capital set a target price of $135.0 on 06/16/2026
- Serge Belanger from Needham set a target price of $136.0 on 06/02/2026
- Geoff Meacham from Citigroup set a target price of $135.0 on 05/18/2026
- Marc Goodman from Leerink Partners set a target price of $90.0 on 04/22/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Veradermics Falls 4.4% as Lock-Up Expiry Appears to Weigh on Shares
Veradermics (MANE) is down 4.4% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver appears to be share-supply pressure tied to the expiration of post-IPO lock-up restrictions. This could be because a late-April SEC prospectus said 20,000,170 previously locked-up shares would become eligible for resale on August 2, 2026, which can pressure a stock even without a new negative operating update.
Details:
Sources:
SEC, Veradermics, Nasdaq
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$MANE Insider Trading Activity
$MANE insiders have traded $MANE stock on the open market 26 times in the past 6 months. Of those trades, 26 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MANE stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MANE Hedge Fund Activity
We have seen 80 institutional investors add shares of $MANE stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MANE Analyst Ratings
Wall Street analysts have issued reports on $MANE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $MANE, check out Quiver Quantitative's $MANE forecast page.
$MANE Price Targets
Multiple analysts have issued price targets for $MANE recently. We have seen 5 analysts offer price targets for $MANE in the last 6 months, with a median target of $135.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »